Potent bronchoconstrictor effects of aerosolized prostaglandin D2 in dogs.
Previously, we demonstrated that prostaglandin D2 (PGD2), a natural product of the endoperoxide PGH2, evoked bronchoconstriction when given I.V. to dogs (PROSTAGLANDINS 13:255-269, 1977). The present investigation in anesthetized dogs demonstrated that aerosols of PGD2 (0.001-0.1%) produced concentration-dependent increases in pulmonary resistance (RL) and decreases in dynamic lung compliance(CDYN) which were short-lived and equipotent to PGF2 alpha. These alterations in pulmonary mechanics were partially, yet significantly, inhibited by atropine, thereby suggesting that at least a portion of the bronchoconstriction may be cholinergically mediated. Concomitant cardiovascular depressant effects of both PGD2 and PFG2 alpha aerosols were much less and more variable than their bronchopulmonary effects. These results demonstrate a potent bronchoconstrictor effect of aerosolized PGD2 in dogs. PGD2 warrants further attention as a possible mediator of the bronchospasm seen in acute, reversible airways obstruction.
D000336:Aerosols; D000403:Airway Resistance / Q000187:drug effects; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001980:Bronchi / Q000187:drug effects*; D003251:Constriction, Pathologic / Q000139:chemically induced; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D007700:Kinetics; D008168:Lung / Q000187:drug effects; D008170:Lung Compliance / Q000187:drug effects; D008297:Male; D011453:Prostaglandins / Q000008:administration & dosage*; D011457:Prostaglandins D / Q000008:administration & dosage*; D011460:Prostaglandins F / Q000494:pharmacology
D000336:Aerosols; D011453:Prostaglandins; D011457:Prostaglandins D; D011460:Prostaglandins F; D001285:Atropine